Cargando…

Omicron: a drug developer’s perspective

We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Fang “Flora”, Shi, Pei-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741250/ https://www.ncbi.nlm.nih.gov/pubmed/34951568 http://dx.doi.org/10.1080/22221751.2021.2023330

Ejemplares similares

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
por: Cao, Cheng, et al.
Publicado: (2023)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
por: Paul, Pradipta, et al.
Publicado: (2023)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China
por: Yin, Zhiying, et al.
Publicado: (2023)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Hybrid immunity and protection against infection during the Omicron wave in Malta
por: Cauchi, John Paul, et al.
Publicado: (2023)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China
por: Lin, Mengna, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China
por: Zheng, Liwei, et al.
Publicado: (2023)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
por: Ma, Ensi, et al.
Publicado: (2022)

Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study
por: Zhang, Quanchao, et al.
Publicado: (2023)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave
por: Lu, Guanzhu, et al.
Publicado: (2022)

Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas
por: Jia, Hongling, et al.
Publicado: (2022)

The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
por: Sarkar, Aparajita, et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants
por: Zhao, Hanjun, et al.
Publicado: (2022)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2022)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants
por: de La Vega, Marc-Antoine, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

A comparative analysis exposes an amplification delay distinctive to SARS-CoV-2 Omicron variants of clinical and public health relevance
por: Brown, K.L., et al.
Publicado: (2022)

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
por: Bingula, Rea, et al.
Publicado: (2023)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage
por: Liang, Ronghui, et al.
Publicado: (2022)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections
por: Tso, Winnie W.Y., et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

The unreversible reduced but persistent activated NK and CD8(+) T cells in severe/critical COVID-19 during omicron pandemic in China
por: Qin, Ling, et al.
Publicado: (2023)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Intranasal infection by SARS-CoV-2 Omicron variants can induce inflammatory brain damage in newly weaned hamsters
por: Li, Can, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vf61g726ts9bl0quf5eufv6j9g